Pituitary Tumors Express Functional Receptors for Growth Hormone Secretagogues
Background
Pituitary adenomas are common, often benign, tumors of the pituitary gland that can lead to hormonal imbalances, such as excessive growth hormone (GH) or adrenocorticotropic hormone (ACTH) secretion. Growth hormone secretagogues (GHSs) are compounds known to stimulate GH release by binding to specific receptors. However, it was previously unclear if human pituitary adenomas themselves express these functional growth hormone secretagogue receptors (GHSRs) and if activating them could influence tumor hormone production.
Results
The study found that GHSR mRNA was expressed in 25 out of 26 human pituitary adenomas, indicating a high prevalence. Triple in-situ hybridization confirmed that GHSR mRNA and protein were co-localized with hormone-producing cells, including those secreting GH and ACTH. Functionally, GHRP-6 significantly stimulated GH release in 5 out of 6 GH-secreting adenomas, showing an increase of up to 2.5-fold compared to control. The most significant finding was that GHRP-6 also stimulated ACTH release in 2 out of 3 corticotroph adenomas, with an increase of up to 2.1-fold, demonstrating functional GHSR expression beyond just GH-secreting tumors. This suggests a direct role of GHSR activation in modulating hormone secretion from various types of pituitary adenomas.
Why It Matters
This research provides compelling evidence that human pituitary adenomas express functional growth hormone secretagogue receptors, which can directly influence hormone secretion. This discovery is crucial because it suggests that targeting GHSRs could represent a novel therapeutic strategy for managing or treating pituitary adenomas, potentially by modulating their hormone output or even inhibiting tumor growth. Future research could focus on developing specific GHSR agonists or antagonists for clinical trials, aiming to control hormone hypersecretion in patients with these tumors.